Darzalex multiple myeloma

DARZALEX FASPRO and DARZALEX are indicated for the treatment of adult patients with newly diagnosed, transplant-ineligible multiple myeloma in combination with Rd and in combination with VMP. 1,2

Darzalex is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells. It is approved for adult patients with myeloma in multiple disease settings, from the newly diagnosed to the relapsed/refractory. Darzalex is administered intravenously.

Multiple myeloma cells have a large number of proteins called CD38 on their surface. Darzalex works by binding to the CD38 protein, which kills the myeloma cells, and Darzalex also helps to increase the ability of the immune system to fight cancer. What is the difference between Darzalex and Darzalex Faspro?

Use of DARZALEX DARZALEX FASPRO in Smoldering Multiple Myeloma. Last Updated: . Summary. DARZALEX for intravenous (IV) use and DARZALEX FASPRO for

Darzalex is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells. It is approved for adult patients with myeloma in multiple disease settings, from the newly diagnosed to the relapsed/refractory. Darzalex is

Darzalex is the first monoclonal antibody approved for treating multiple myeloma and is typically administered in combination other anti-myeloma medications to

Darzalex is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells. It is approved for adult patients with myeloma in multiple disease settings, from the newly diagnosed to the relapsed/refractory. Darzalex is administered intravenously.

New oral agent shows promise in treatment of relapsed multiple myeloma FDA Approves Three New Treatments for Multiple Myeloma Darzalex-Based

This was driven by a number of key performers, including Darzalex multiple myeloma medication, Teclistamab. In an earnings report